The preclinical development of peptidyl drugs for cancer treatment is hampered by their poor pharmacological properties and cell penetrative capabilities in vivo. In this study, we report a nanoparticle-based formulation that overcomes these limitations, illustrating their utility in studies of the anti-cancer peptide NuBCP-9 which converts BCL-2 from a cell protector to a cell killer. NuBCP-9 was encapsulated in polymeric nanoparticles (NPs) comprised of a polyethylene glycol (PEG)-modified polylactic acid diblock copolymer (NuBCP-9/PLA-PEG), or PEG-polypropylene glycol-PEG-modified PLA -tetrablock copolymer (NuBCP-9/PLA-PEG-PPG-PEG).
Ͷ (11) (12) (13) . Cell-penetrating peptides (CPPs) that have been widely used for cargo delivery include, among others, the TAT peptide, penetratin and oligoarginines (11) . The selection of a certain CPP is of importance in that the CPP can in a cargo-dependent manner contribute to decreased serum stability, inefficient transit from the endosome to the cytosol and unanticipated toxicities (14) . Indeed, for NuBCP-9, the cell-penetrating r8 used for intracellular delivery acts in synergy with the N-terminal phenylalanine of NuBCP-9 to cause membrane blebbing and cell necrosis that are independent of BCL-2 expression (15). These findings have supported the study of alternative CPPs for NuBCP-9 or other formulations that preclude the use of a CPP for intracellular delivery.
Nanoparticle (NP) delivery systems for anti-cancer agents, particularly small molecules such as doxorubicin and paclitaxel, have been developed to improve pharmacokinetic parameters and therapeutic index (16) . In this context, tumor microenvironments that are subject to hypoxia and acidosis can limit the effectiveness of small molecule anti-cancer agents (16) . By extension and through what is referred to as the enhanced permeation retention (EPR) effect, NP delivery of anti-cancer agents can overcome limitations imposed by the tumor microenvironment and sustain drug exposure (16, 17) . NPs can also be decorated with ligands to selectively target the surface of tumor cells (18) . Polymeric NPs represent one class that has been widely studied and shown to be non-toxic, biocompatible and biodegradable (19, 20) . Specifically, PLA-PEG block copolymer NPs have been used as carriers for anti-cancer drugs in sustained/controlled release and targeted delivery systems to enhance efficacy and circumvent drug resistance (19, 20) . For example, Genexol-PM is a paclitaxel-loaded PLA-PEG polymeric NP that is approved for use in Korea and is undergoing Phase II evaluation in the United States for metastatic cancers (19, 21) . BIND Biosciences also has under development docetaxel-encapsulated PLA-PEG NPs for the treatment of solid tumors (19) . Curiously, polymeric NPs have not been fully evaluated for the delivery of anti-cancer peptide drugs.
The present studies have focused on the encapsulation of NuBCP-9 into ͷ
Materials and Methods
Synthesis and characterization of PLA-PEG copolymers. PLA-PEG diblock copolymers were synthesized using 72 kDa PLA (NatureWorks, Blair, NE) or ~12 kDa PLA (Purac Chemicals, Netherlands). PEG was used at 1, 2 or 4 kDa (CDH, Mumbai, India) for coupling to PLA. PEG-PPG-PEG (12.5 kDa; Poloxamer-F127, Sigma-Aldrich, St. Louis, MO) was also used for the synthesis of PLA block copolymers. In a standard experiment, 0.014 mmol PLA and PEG or PEG-PPG-PEG were dissolved in 100 ml dichloromethane (CH 2 Cl 2 ) and stirred at 0-2 o C. To these solutions, 5 ml of 1% N,N-dicyclohexylcarbodimide (DCC) was added slowly, followed by the addition of 2 ml of 0. Preparation of Rhodamine B and NuBCP-9 loaded NPs. Loading of the PLA-PEG and PLA-PEG-PPG-PEG NPs was performed using a double emulsion solvent evaporation method. PLA-PEG or PLA-PEG-PPG-PEG copolymers (100 mg) were dissolved in 5 ml acetonitrile. Rhodamine B (1 mg) or L-amino acid NuBCP-9 (10 mg; BioConcept, Gurgaon, India) was added to the solution with brief sonication. The resulting primary emulsion was then added dropwise into a 20 ml aqueous phase comprised of Poloxamer-F127 (PEG-PPG-PEG) in distilled water and stirred at room temperature for 6-8 h to facilitate solvent evaporation and NP stabilization. NPs were loaded with NuBCP-9 (FSRSLHSLL) peptide (7) and filtered through an Amikon 10 kDa ultra-filter (Millipore, Billerica, MA). The NPs were lyophilized and stored at -20 o C until use. The filtrate was collected and analyzed for free NuBCP-9 peptide using a micro BCA kit (Pierce Chemicals, Rockford, IL). Encapsulation efficiency of NuBCP-9 peptide was determined using the following formula:
(Peptide)Total
Morphology and particle size of the NPs was determined using a Zeiss EVO 50 Series Scanning Electron Microscope (SEM). Zeta-potential of the NPs was assessed by dynamic light scattering (DLS; NanoSight NS500, Cambridge, UK).
Assessment of NuBCP-9 release from NPs. The in vitro release kinetics of NuBCP-9 from NPs were determined by the ultrafiltration method. Briefly, samples of freeze dried NPs (10 mg) were suspended in PBS and incubated at 37 0 C with gentle shaking at 150-160 rpm. At pre-determined time points over 60 d, the samples were removed from the incubator and ultra-filtered through 10 kDa Amikon filters (Millipore). The filtrates were collected for analysis and fresh buffer was added to the respective tubes. Peptide concentration in the filtrates was determined by micro BCA assay.
Cell culture. Human MCF-7 breast cancer and HepG2 hepatocellular carcinoma cells were grown in DMEM medium containing 10% fetal bovine serum, 100 units/ml penicillin and 100 g/ml streptomycin. Human umbilical vein endothelial cells (HUVEC) were cultured in EBM-2 medium with endothelial cell growth supplement (Lonza, Hopkinton, MA). Proliferation was assessed by the XTT-based in vitro assay kit (Cayman, Ann Arbor, MI). To assess uptake of NPs, MCF-7 cells were seeded on coverslips and grown for 24 h.
After incubation with Rhodamine B loaded NPs, the coverslips were removed, washed with PBS and fixed with 4% paraformaldehyde. The cells were then stained with DAPI and visualized under a confocal laser scanning microscope (CLSM, Olympus, Fluoview FV1000 Microscope, Japan).
Assessment of apoptosis.
Cells were stained using the annexin V-alexa fluor 488/PI apoptosis assay kit (Invitrogen, Grand Island, NY).
Quantification of apoptosis/necrosis was performed using Cellometer Vision (Nexcelom Bioscience LLC, Lawrence, MA). Cells were also imaged using the CLSM microsocope. different agents using two schedules for 21 d (Supplemental Table 1 ͺ
Results
Preparation and characterization of NuBCP-9-loaded polymeric NPs. PLA-PEG NPs have been commonly synthesized using PLA of ~20 kDa or less (19) (20) (21) .
In the present work, we studied the development of polymeric NPs that Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ͻ example, when the feeding ratio of NuBCP-9/block copolymers (w/w) was 1:10, the encapsulation efficiency of the different polymeric NPs ranged from 43% to 66% (Table 1 DLS measurements of the NPs documented a hydrodynamic diameter ranging from 114 to 125 nm, which did not change significantly after NuBCP-9 loading (Table 1 ). In addition, the hydrodynamic diameter of the NPs was not significantly altered by coupling to the different PEG molecular weights (1, 2 and 4 kDa), consistent with the greater mass of PLA as compared to PEG (Table 1) . By contrast, the zeta potential of the NPs increased with increasing PEG block length (Table 1) , a finding in concert with the demonstration that the zeta potential of NPs approaches neutral with increases in hydrophilicity due to PEG coupling (24) . Notably, the zeta potential of the PLA 72K -PEG 4K NPs was similar to that for PLA
72K
-PEG-PPG-PEG NPs before and after NuBCP-9 loading (Table 1 ). We also found that NuBCP-9
loading is associated with a marked decrease in zeta potential as compared to that obtained with the unloaded NPs ( Table 1 ). The precise reason for this decrease in zeta potential is not clear; however, it is plausible that due to the interaction of the positively charged adsorbed peptide with the negatively charged PLA, the peptide carboxyl groups, which have a negative charge, are exposed on the surface of the nanoparticles. Lower molecular weight PLA (12 kDa) was also used to synthesize PLA-PEG block copolymers to assess the effect on NuBCP-9 loading and release. The encapsulation efficiency of NuBCP-9 into PLA 12K -PEG-PPG-PEG was similar to that obtained with PLA 72K -PEG-PPG-PEG (Table 1) . However, release of NuBCP-9
from PLA 12K -PEG-PPG-PEG was sustained for only 10 days as compared to 60 days for PLA 72K -PEG-PPG-PEG. After 10 days, peptide was no longer detectable in the filtrate, a finding probably due in part to the degradation and biosolubilization of low molecular weight PLA, which interferes with peptide detection in the assays ( Figs. 2A-D) . Based on these results, the NuBCP-9-encapsulated PLA 72K -PEG 4K and PLA
-PEG-PPG-PEG NPs were further studied for biologic activity in vitro and in vivo.
Effects of NuBCP-9-encapsulated NPs on cancer cell growth and survival in vitro. To assess activity of the NuBCP-9-loaded NPs, we studied their effects on growth of BCL-2-expressing MCF-7 (28) and HepG2 (29) ͳͳ inhibiting cancer cell proliferation in the absence of a CPP, such as r8 (6) , and these observations were confirmed when NuBCP-9 was tested against MCF-7 and HepG2 cells (Figs. 3A and B) . However, as expected from previous studies (6), the L-amino acid NuBCP-9-R8 (R denotes L-amino acid; r denotes D-amino) completely blocked growth of these cells after treatment at 15 μM for 48 h (Figs. 3A and B) , confirming that R8 is necessary for cell penetration and BCL-2 targeting. Notably, the NuBCP-9 that has been encapsulated in NPs in the present studies is devoid of R8 and therefore would be expected to be inactive unless effectively delivered by the NPs.
Indeed, the NuBCP-9-encapsulated NPs were highly effective in inhibiting growth of MCF-7 and HepG2 cells (Figs. 3A and B) . By contrast, empty NPs not encapsulated with NuBCP-9 had little if any effect on growth (data not shown). Other studies were performed to assess the effects of using different concentrations of NuBCP-9 NPs on cell viability. As expected, NuBCP-9-R8 induced death of MCF-7 cells in a concentration-dependent manner (Fig. 3C ). In addition, the NuBCP-9 NPs (PLA 72K -PEG 4K and PLA
-PEG-PPG-PEG)
were effective in killing MCF-7 cells (Fig. 3C) . Similar results were obtained when HepG2 cells were treated with different concentrations of PLA-PEG NPs (Fig. 3D) . The IC 50 values for the NuBCP-9 NPs ranged from 1.9 to 4.2 μM, as compared to 7.1 to 9.1 μM for NuBCP-9 R8 (Table 2 ). In addition and in concert with the lack of NuBCP-9 activity against normal cells (6), NuBCP-9-encapsulated NPs had no apparent effect on HUVEC cell growth (Fig.   3E ). These results indicate that NuBCP-9 can be delivered intracellularly Fig. 4C ). Moreover and in concert with the effects of (Fig. 4D) . These findings thus demonstrate that, like NuBCP-9-R8, encapsulation of NuBCP-9 in NPs results in the induction of apoptosis (Fig. 4D) .
NuBCP-9-NPs are effective in inducing complete tumor regressions. To assess the anti-tumor effects of NuBCP-9 NPs in vivo, we treated Balb/c mice bearing established (~400 mm 3 ) subcutaneous BCL-2-positive Ehrlich syngeneic tumors (30) . In this widely used model to assess the effects of anti-cancer agents, accurate administration of the viscous suspensions of NPs was problematic in the narrow tail vein. As such, we used the intraperitoneal (IP) route of administration, which allows NPs to enter the systemic circulation through mesenteric vessels and the portal vein (31) . Moreover, these studies were performed with NuBCP-9 (devoid of R8) because (i) NuBCP-9-R8 is active in vivo when administered intratumorally (6), and (ii) the NuBCP-9 should be inactive in the absence of a CPP. IP injection of NuBCP-9 on a twice weekly schedule for 21 days had no significant effect on tumor growth as compared to that obtained with the saline control (PBS) (Fig. 5A and Supplemental Table 1 ). Significantly, IP treatment with NuBCP-9 PLA 72K -PEG 4K NPs at a dose of 20 mg/kg (NuBCP-9 peptide dose) on the same schedule was associated with complete and prolonged tumor regressions (Fig. 5A ).
Moreover, in contrast to the empty PLA Fig S3) . Analysis of survival as determined by
Kaplan-Meier plots further demonstrated that mice treated with NuBCP-9 NPs (PLA 72K -PEG 4K or PLA 72K -PEG-PPG-PEG) weekly or twice weekly survived significantly longer than the saline, empty NPs or NuBCP-9 controls ( Fig. 5D and E). Moreover, the NuBCP-9 NPs-treated mice survived longer when administration was IP as compared to the IT route ( Fig. 5D and E).
Significantly, there was no weight loss or other overt toxicities observed in the NuBCP-9/NP-treated mice (data not shown). Analysis of tissue (Fig. 5F, left) (32) . In this context, there are increasing reports of peptide drugs under development that target non-kinase proteins such as survivin (33) , HDM2 (34), NOTCH (35) , MUC1 (36) and β-catenin (37), among others. The BCL-2 family proteins have also been the focus of peptide inhibitor development, specifically in one strategy using stabilized alphahelices of BCL-2 domains (SAHBs) (38). BCL-2 has also been converted from an anti-apoptotic protein to an inducer of cell death by the Nur77-derived NuBCP peptide (6, 7) . With the exception of SAHBs, which penetrate cell membranes, delivery of peptide drugs has in general required the addition of a PTD for intracellular delivery (11) . In this way, NuBCP was linked to the CPP D-Arg octamer (r8) (6) . NuBCP-9-r8 is a potent and selective inducer of cancer cell apoptosis in vitro (6) . NuBCP-9-r8 is also effective in inducing apoptosis in vivo when injected directly into tumors (6) . Indeed, a challenge for the development of many peptide drugs, like NuBCP-9, is the potential for systemic delivery, which can be limited by pharmacologic ͳͷ copolymer in preparation of PLA NPs is that emulsifier concentrations can be markedly reduced for PLA NP stabilization at pH 7.4. Indeed, for PLA-PEG NPs, the final emulsifier concentration was 0.4%, however, we were able to further reduce that concentration by 5-fold to 0.08% for the PLA-PEG-PPG-PEG NPs. These findings are therefore of potential significance for the clinical development of these polymeric NPs.
Based on the results obtained with our double emulsion method, we studied loading of NuBCP-9 in the PLA-PEG and PLA-PEG-PPG-PEG NPs. Previous work had demonstrated that increasing PEG chain length from 1 to 4 kDa significantly improves the hydrophilicity and flexibility of block copolymers (44) . Consequently, we analyzed the effects of different lengths of the PEG block and found that increases in PEG chain length improves NuBCP-9 loading. Moreover, our results demonstrate that release of NuBCP-9 over time is enhanced by increases in PEG chain length, a finding in concert with greater flexibility, hydrophilicity and hydration of the NP. In turn, the rate of diffusion increases, as does release of the peptide from the NP matrix (20, (45) (46) (47) (48) . Thus, for NuBCP-9 and potentially other peptide drugs, these findings indicate that PEG chain length is of importance for both loading in and release from polymeric NPs. Another aspect of our studies worth highlighting is the use of a high molecular weight PLA (72 kDa) in the NuBCP-9 encapsulated NPs. Previous work on polymeric NPs has generally involved lower molecular weight PLA, for example, using 20 kDa or less (49, 50). Our results indicate that in vitro release of NuBCP-9 from our NPs was sustained to over 60 d when using ~72 kDa PLA as compared to release of the peptide over 10 d with ~12 kDa PLA. These results can be explained, at least in part, by the hydrolysis of PLA and thereby NuBCP-9 diffusion. At pH 5.0, PLA remains coiled and is less susceptible to hydrolysis; whereas at pH 7.4, the PLA chains open with an increased propensity for hydrolysis.
The uncoiling of PLA is thus associated with an increase in its degradation and release of NuBCP-9 (26, 27). These findings collectively indicate that peptide release from polymeric NPs can be controlled by varying the sizes of the PEG and PLA blocks.
NuBCP-9 is a highly promising anti-cancer peptide that selectively induces apoptosis of cancer cells by exposing the BCL-2 BH3 domain and blocking the BCL-xL survival function (6) . NuBCP-9 was linked to the D-Arg octamer r8 for intracellular delivery, a modification that has been reported to decrease selectivity by inducing BCL-2-independent cell killing involving membrane disruption (15). In the present work, delivery of NuBCP-9 into cancer cells by the polymeric NPs was achieved without the need for the R8 
ͳ PTD. In addition, the NuBCP-9 encapsulated NPs were by comparison more potent in inducing apoptosis than NuBCP-9-R8. The NuBCP-9/NPs also maintained the reported selectivity of NuBCP-9 for cancer cells as evidenced by their absence of HUVEC killing (6) . Previous studies of the anti-tumor effects of NuBCP-9 in vivo were performed by direct injection of NuBCP-9-r8 into MDA-MB-435 breast cancer xenografts growing in SCID mice (6) . Under these experimental conditions, NuBCP-9-r8 treatment was associated with partial MDA-MB-435 tumor regressions (6) . In the present studies using the subcutaneous Ehrlich tumor model in syngeneic mice, we compared the effectiveness of NuBCP-9/NPs administered intraperitoneally (IP) and intratumorally (IT). Significantly, both routes of NuBCP-9/NP administration were effective in inducing complete regressions of the Ehrlich tumors. Moreover and interestingly, IP administration was more effective than IT delivery in maintaining prolonged tumor regressions. The basis for this distinction is presently not clear, but is likely related to pharmacokinetics and pharmacodynamics of the NuBCP-9/NPs, which will be the focus of subsequent studies. Of further importance, administration of the NuBCP-9/NPs was well-tolerated with no evidence of weight loss or overt toxicities. These results thus provide support for the effective delivery of L-amino acid NuBCP-9 by PLA-PEG-PPG-PEG NPs and may be applicable to other anti-cancer peptides. In summary, our findings describe a novel NPbased approach for delivery of L-amino acid peptides without a cellpenetrating domain that (i) requires reduced levels of emulsifier, (ii) incorporates higher molecular weights of PLA for sustained and prolonged peptide release, (iii) induces effective anti-cancer activity in vitro and in vivo, and (iv) requires less frequent dosing (once/week) compared to the daily injections that were necessary for partial anti-tumor activity of the D-amino acid NuBCP-9-r8 peptide in vivo (6). 
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